Romidepsin attenuates growth of rare sarcomas

Yuki Yoshimatsu and coworkers have shown that they could establish patient-derived cancer cell lines for myxofibrosarcoma and pleomorphic sarcoma. After screening these cell lines with a number of cancer drugs they found that romidepsin, a novel microbial product HDAC inhibitor demonstrated considerable antiproliferative effect on these cells.